Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

NCT07050732 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL: Arexvy (2 doses total)
BIOLOGICAL: Arexvy (3 doses total)
BIOLOGICAL: Arexvy (1 dose total)
OTHER: Placebo

Sponsor

Johns Hopkins University

Collaborators

[object Object]